key: cord-0966110-7dn1rcrf authors: Balaz, David; Wikman-Jorgensen, Philip Erick; Galvañ, Vicente Giner; Rubio-Rivas, Manuel; de Miguel Campo, Borja; López, Mariam Noureddine; Caleya, Juan Francisco López; Huelgas, Ricardo Gómez; Fontán, Paula María Pesqueira; Bailón, Manuel Méndez; Fernández-Garcés, Mar; Cruz, Ana Fernández; García, Gema María García; Rhyman, Nicolás; Corral-Gudino, Luis; Rodríguez-Mancheño, Aquiles Lozano; De La Chica, María Navarro; García, Andrea Torregrosa; Alcalá, José Nicolás; Jiménez, Pablo Díaz; Trallero, Leticia Esther Royo; Casanova, Pere Comas; Núñez-Cortés, Jesús Millán; Casas-Rojo, José-Manuel title: Evolution of the Use of Corticosteroids for the Treatment of Hospitalised COVID-19 Patients in Spain between March and November 2020: SEMI-COVID National Registry date: 2021-10-08 journal: J Clin Med DOI: 10.3390/jcm10194610 sha: e962f783c40399d7ffeb3713ca97c1e322b789f2 doc_id: 966110 cord_uid: 7dn1rcrf Objectives: Since the results of the RECOVERY trial, WHO recommendations about the use of corticosteroids (CTs) in COVID-19 have changed. The aim of the study is to analyse the evolutive use of CTs in Spain during the pandemic to assess the potential influence of new recommendations. Material and methods: A retrospective, descriptive, and observational study was conducted on adults hospitalised due to COVID-19 in Spain who were included in the SEMI-COVID-19 Registry from March to November 2020. Results: CTs were used in 6053 (36.21%) of the included patients. The patients were older (mean (SD)) (69.6 (14.6) vs. 66.0 (16.8) years; p < 0.001), with hypertension (57.0% vs. 47.7%; p < 0.001), obesity (26.4% vs. 19.3%; p < 0.0001), and multimorbidity prevalence (20.6% vs. 16.1%; p < 0.001). These patients had higher values (mean (95% CI)) of C-reactive protein (CRP) (86 (32.7–160) vs. 49.3 (16–109) mg/dL; p < 0.001), ferritin (791 (393–1534) vs. 470 (236–996) µg/dL; p < 0.001), D dimer (750 (430–1400) vs. 617 (345–1180) µg/dL; p < 0.001), and lower Sp0(2)/Fi0(2) (266 (91.1) vs. 301 (101); p < 0.001). Since June 2020, there was an increment in the use of CTs (March vs. September; p < 0.001). Overall, 20% did not receive steroids, and 40% received less than 200 mg accumulated prednisone equivalent dose (APED). Severe patients are treated with higher doses. The mortality benefit was observed in patients with oxygen saturation 0.05 for all categories). In severe patients, with an oxygen saturation of 90% or less, corticosteroids were associated with a lower mortality risk at doses higher than 400 mg of APED (OR 1 (p = 0.7), 0.7 (p = 0.007), 0.5 (p = 0.0006), 0.6 (p = 0.0002), Table 3 ) in comparison to the group that did not receive CTs. patients with an oxygen saturation on admission above 94%, corticosteroids were associated with higher mortality across all dose ranges (OR 2.1, 1.7, 1.9, 2.0, p < 0.05 for all categories). In patients with an oxygen saturation between 91 and 94%, they were not associated with a higher nor a lower risk (OR 1.2, 1.3, 0.9, 0.9, p > 0.05 for all categories) . In severe patients, with an oxygen saturation of 90% or less, corticosteroids were associated with a lower mortality risk at doses higher than 400 mg of APED (OR 1 (p = 0.7), 0.7 (p = 0.007), 0.5 (p = 0.0006), 0.6 (p = 0.0002), Table 3 ) in comparison to the group that did not receive CTs. Our retrospective analysis showed that CTs were used mostly in severe and critical cases of COVID-19. Patients that received CTs were generally older, more frequently male, and more affected by comorbidities. The prevalence of hypertension, cardiovascular diseases, and diabetes has been reported to be two-to threefold higher in patients with a severe type of COVID-19 than in their non-severe counterparts, and these comorbidities have been described as risk factors for mortality [20] [21] [22] [23] . The most common comorbidity in our cohort was high blood pressure with a prevalence of 51.1% which is higher than in other published data. The prevalence of high blood pressure in other works ranges between 10 and 34% [24] . Higher prevalence in our cohort is congruent with national data of arterial hypertension in Spain, where one in three adults is hypertensive (66% in those >60 years) [25] . Patients receiving CTs were more affected by comorbidities but also presented with worse baseline biochemical, gasometric, and radiological parameters at the time of admission in comparison with the non-CT group. Oxygen levels were lower in the group receiving CT. Additionally, other analytical markers associated with severe COVID [26] such as CRP, procalcitonin, LDH, creatinine, urea, ferritin, and D-dimer, were higher in the group of patients receiving CT. Moreover, X-ray findings were also worse in the group receiving CT. It is noteworthy that two well-known biomarkers, lymphopenia and thrombocytopenia, did not reach a significant difference between the two analysed groups. This could be due to a point data collection at hospital admission, as lymphopenia and thrombocytopenia usually develop during the course of infection and hospitalisation. The use of CTs changed dramatically after the month of June 2020. That month, a press release revealed data from the RECOVERY trial [6] . In September, 80% of hospitalised COVID-19 patients received CTs, whereas only 35% received them in March. The dose of CT used did also change over time. The initial daily dose of 1 mg/Kg of ideal body weight was associated with the highest mortality reduction in RCTs of non-viral ARDS and large observational studies in SARS-CoV-2 and H1N1 pneumonia [27] . A Spanish semi-randomised study investigated methylprednisolone (3 days each, 80 mg and 40 mg, respectively) in 85 COVID-19 (56 CST, 29 control) hypoxemic patients. CT was associated with a reduced risk of admission to ICU, non-invasive ventilation, or death. [28] The RECOVERY trial showed significant mortality decreases with 6 mg of dexamethasone once daily for up to 10 days. In the light of those results, the WHO published new guidance regarding the use of corticosteroids. There is little doubt as to whether corticosteroids are effective for the treatment of critically ill patients with COVID-19, as well as for severe patients. The WHO recommendations do recommend corticosteroids only for these subgroups. Severe COVID-19 was defined as those with an oxygen saturation equal to or below 90%. However, caution was advised, as 90% was admitted to being an arbitrary threshold. We, therefore, performed a stratified analysis and multivariate analysis to determine the optimal oxygen saturation threshold at which CTs seemed to be useful and at what dose. In a previous communication from our centre, we reported better outcomes with doses slightly higher than those used in the RECOVERY trial. [29] This study found that corticosteroids were associated with higher mortality in patients with an oxygen saturation above 94%. This is in accordance with the results of the RECOV-ERY trial, in which a possibility of harm was reported among patients that did not need oxygen support [29] . On the other hand, we cannot rule out that some other factor may be contributing to this finding that was not taken into consideration in the multivariate analysis. Therefore, we would approach this finding with caution. CTs appeared to be neutral when saturation was between 91% and 94%, and clearly beneficial when used in patients with an oxygen saturation of 90% or less. An interesting finding is that, again, the dose found to be effective is a dose higher than the dose of the RECOVERY trial, as the minimum effective dose was an APED of 400-600 mg. The dose used in the RECOVERY trial was an APED of 380 mg. Moreover, there seems to be a trend for more effectiveness at higher doses (Figure 4) , raising the question of whether high dose pulses of steroids (>500 mg of prednisone/day or similar) would be even more effective. Our study has several limitations. This is an observational, retrospective study in which data were collected by a large team of researchers, which could have led to heterogeneity in data entry and validation. The study was not designed for investigating the effectiveness of corticosteroids or other clinical outcomes related to their use, such as adverse effects, days of hospital admission, or mortality. In our study, the baseline characteristics between the CT use group and the non-CT use group were unbalanced. On the other hand, our study has several strengths. The first is the sample size, and the second one is that the study population spans the entire geographical area of the healthcare system. Another advantage is that the conclusions have been drawn from the daily clinical activity, and therefore, suggestions for improving COVID-19 management can be used in a real-world setting. In conclusion, we can affirm that from February to November 2020, corticosteroid use in Spanish hospitals was more common in patients with worse biochemical, gasometric, and radiological status on hospital admission. This group also presented with more comorbidities. The administration of corticosteroids increased dramatically after the publication of the RECOVERY trial, showing effectiveness in hospitalised patients with COVID-19 needing oxygen support. Patients with oxygen saturation equal to or below 90% had better outcomes if CTs were administered, especially a dose above 400 mg APED. In patients with oxygen saturation above 90%, they were either neutral or harmful. Informed Consent Statement: Personal data processing strictly complied with the applicable European Union and Spanish laws on biomedical research and personal data protection. All patients gave informed consent. When there were biosafety concerns and/or when the patient had already been discharged, verbal informed consent was requested and noted on the medical record. The conduct and reporting of the study were carried out pursuant to the STROBE statement guidelines. An online electronic data capture system (DCS) was developed for the SEMI-COVID-19 Registry. Data analysis and logistics coordination were also carried out by independent external agencies. Alphanumeric sequences of characters were used as identification codes to pseudo-anonymise dissociated patient identifiable data; as such, the DCS did not contain any direct patient identifiers. The database platform is hosted on a secure server, and all information is fully encrypted through a valid TLS certificate. Itziar Diego Yagüe, Ignacio Donate Velasco, Ana María Duca, Pedro Durán del Campo, Gabriela Escudero López, Esther Expósito Palomo, Ana Fernández Cruz, Esther Fiz Benito, Andrea Fraile López Millán References 1. WHO. Interim Clinical Guidance for Management of Patients with Confirmed Coronavirus Disease (COVID-19) Systematic Review of Treatment Effects The Use of Corticosteroid as Treatment in SARS was Associated with Adverse Outcomes: A Retrospective Cohort Study Clinical Recommendations from an Observational Study on MERS: Glucocorticoids was Benefit in Treating SARS Patients Effects of Early Corticosteroid Treatment on Plasma SARS-Associated Coronavirus RNA Concentrations in Adult Patients Dexamethasone in Hospitalized Patients with COVID-19 Corticosteroids: A Controversial Therapy for Coronavirus Disease Cytokine Release Syndrome in Severe COVID-19 Pulmonary Post-Mortem Findings in a Series of COVID-19 Cases from Northern Italy: A Two-Centre Descriptive Study The Pathogenesis and Treatment of the 'Cytokine Storm' in COVID-19 Immunomodulation for Severe COVID-19 Pneumonia: The State of the Art WHO. Corticosteroids for COVID-19: Living Guidance. 2020. Available online Effectiveness of Adjunctive Corticosteroid Therapy in Patients with Severe COVID-19: A Retrospective Cohort Study Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with Coronavirus Disease 2019 (COVID-19) Risk Factors Associated with Acute Respiratory Distress Syndrome and Death in Patients with Coronavirus Disease Clinical Characteristics of Patients Hospitalized with COVID-19 in Spain: Results from the SEMI-COVID-19 Network Testing for Coronavirus Disease 2019 (COVID19) in Suspected Human Cases The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for Reporting Observational Studies Validation of a Combined Comorbidity Index COVID-19 and Arterial Hypertension: Hypothesis or Evidence? Prevalence of Comorbidities in the Novel Wuhan Coronavirus (COVID-19) Infection: A Systematic Review and Meta-Analysis Prevalence of Underlying Diseases in Hospitalized Patients with COVID-19: A Systematic Review and Meta-Analysis Association of Hypertension with All-Cause Mortality among Hospitalized Patients with COVID-19 COVID-19 and Diabetes: Is There Enough Evidence? Epidemiología de la Hipertensión Arterial. Hipertens. Y Riesgo Vascular A Meta-Analysis of Potential Biomarkers Associated with Severity of Coronavirus Disease 2019 (COVID-19) Rationale for Prolonged Corticosteroid Treatment in the Acute Respiratory Distress Syndrome Caused by Coronavirus Disease A Controlled Trial of Methylprednisolone in Adults Hospitalized with COVID-19 Pneumonia Corticoides en la Infección por SARS-COV-2: Un Estudio de Cohortes Retrospectivas